Activation with a FXR agonist significantly reduces arsenic-induced glucose intolerance and associated dysregulation of hepatic proteins and serum metabolites, highlighting that FXR serves as a potential target for the treatment of arsenic-induced diabetes. The gene discussed is NR1H4; the disease is Glucose intolerance.